Introduction
Chronic autoimmune thrombocytopenic purpura (AITP) is a bleeding disorder characterized by the production of autoantibodies that mediate platelet destruction 1, 2 . The clinical signs include petechial hemorrhages, hemorrhagic bullae on mucous membranes, gingival or gastrointestinal bleeding, menorrhagia, retinal hemorrhages, and, most seriously, intracranial hemorrhage. Current therapeutic strategies for AITP rely on non-specific immunosuppressive agents 3, 4 , or intravenous immunoglobulin or anti-D 5 , with refractory cases undergoing splenectomy to remove a major site of autoantibody production and platelet destruction 6 .
Unfortunately, the results of these approaches are frequently unsatisfactory [3] [4] [5] [6] . A fuller understanding of the pathogenesis of AITP is therefore required, in order to develop safe, effective treatments that specifically inhibit the disease process.
A major focus of research into the pathogenesis of AITP has been the characterization of the autoantibody response 1, [7] [8] [9] [10] . Platelet membrane glycoprotein IIb/IIIa (GPIIb/IIIa) has emerged as the major autoantigen that is bound by pathogenic autoantibodies from most patients 8 .
Other platelet antigens that can be targeted, but less frequently, include glycoproteins from healthy controls, exhibit accelerated proliferation when stimulated in vitro with fragments of purified 17 or recombinant 18 GPIIb/IIIa, indicative of prior activation in vivo.
These memory Th cells are capable of driving anti-GPIIb/IIIa IgG synthesis by peripheral blood B cells from patients in vitro 17, 18 , with the spleen as the primary site for the autoreactive B cells to receive such help in vivo 19 . T cells in AITP may, in addition to providing help for the autoantibody response, also contribute directly to platelet destruction 20 .
In response to the accumulating evidence that Th cells represent potential therapeutic targets, a small number of AITP patients has been treated with a humanized monoclonal antibody (mAb) that blocks the helper co-stimulatory molecule, CD40 ligand (CD154) 21 . The effects were to reduce both the frequency and in vitro collaboration of peripheral blood Th and B cells responsive to GPIIb/IIIa, and in some cases, treatment was associated with increased platelet counts 21 . Any such immune inhibition may be only temporary, and not necessarily limited to the pathogenic response, but it should be possible to develop longer lasting and more selective immunotherapy by tolerizing the Th cells specific for platelet autoantigen, once the helper response has been sufficiently well characterized 11 .
CD4 + Th cells recognize short peptides that have been processed and displayed bound to MHC class II molecules by antigen presenting cells (APC) 22 . Antigen-specific tolerance can be induced in vivo by synthetic peptides containing dominant helper epitopes, if administered appropriately in soluble form, particularly via mucosal surfaces in the nose or gut 23 . There are now many examples of successful treatments based on this approach for inhibiting animal models of immune-mediated disease, including autoimmune hemolytic anemia 12 and responses to blood group antigens 24 , and human trials are underway in patients with allergy 25 , rheumatoid arthritis 26 and type I diabetes 27 . In order to exploit a similar strategy in AITP, it will first be necessary to map peptides that contain the dominant Th epitopes from platelet only.
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The aim of the current work was to map the fine specificity of platelet-specific Th cells from patients with chronic AITP. Our approach, which has proved successful for other antigens [28] [29] [30] , was to screen a panel of short, overlapping peptides spanning the entire sequence of platelet glycoprotein for the ability to stimulate recall responses by peripheral blood Th cells.
We focused on responses to one major autoantigenic molecule, GPIIIa, which is known to contain important B and T cell determinants 18, 31 . The results identify GPIIIa peptides that contain epitopes recognized by autoreactive Th cells from AITP patients, and which are candidate tolerogens for specific immunotherapy of the disease.
Materials and Methods

Patients and control subjects
Approval for the study was received from the Grampian Local and Regional Ethics Committee (number 00/0052). Informed written consent was obtained from all patients and healthy controls. Samples of whole blood were obtained from 31 patients (21 female and 10 male) with AITP, who attended the outpatient hematology clinic at Aberdeen Royal
Infirmary. The details of the patients, who are all North European Caucasian, are summarized in Samples of whole blood for PBMC isolation were also taken from 25 healthy control blood donors (18 female and seven male). None was on any medication. PBMC samples from a further group, of five patients with aplastic anaemia (four male and one female), were included as disease controls, since this condition responds to immunosuppression and is considered to have an autoimmune basis 32 , and patients also have low platelet counts.
Platelet recovery and preparation of eluates
Platelets from AITP patients and controls were isolated by differential centrifugation of anticoagulated (citrate-phosphate-dextrose) blood. Antibody was eluted from the surface of platelets as described by Hürlimann-Forster et al 9 and stored at -80 0 C until used.
Detection of antiplatelet autoantibodies against GPIIb/IIIa from serum and platelet eluates of AITP patients and controls
Anti-GPIIb/IIIa autoantibody concentrations in sera and eluates were measured by ELISA using published methods 33, 34 . Briefly, samples were screened in duplicate wells of microtitre plates coated with purified GPIIb/IIIa. Background binding was determined by incubating each sample in uncoated wells, and control samples positive and negative for antibody were also included. Absorbance was read at 540nm using a multiscan plate reader (Labsystems, Finland). Specific optical densities (OD) > 0.1 and > 0.05 were interpreted as positive results for serum and eluate samples respectively (determined from the mean of healthy control samples + 2 SD). 
Preparation of antigens and mitogens
The human platelet membrane GPIIIa amino acid sequence reported by Frachet et al
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(Genebank Accession no: M35999) was synthesized (Pepceuticals, Nottingham, UK) as a complete panel of 86 15-mer peptides, overlapping by 5-10 amino acids (Table 3) . Peptide purity was monitored by amino acid analysis and mass spectrometry as reported previously [28] [29] [30] . The peptides were used for stimulation of T cells at the previously determined optimum concentration of 20 µg/mL in culture [28] [29] [30] .
The antigen mycobacterial purified protein derivative (PPD) (Statens Serumintitut, Denmark) was added to cultures at 20µg/mL to stimulate positive control recall T cell responses 36 .
Concanavalin A (Con A) (Sigma, Poole, Dorset, UK) was used at 20µg/mL as a positive control T cell mitogen.
Isolation of peripheral blood mononuclear cells (PBMC)
Mononuclear cells were recovered from anti-coagulated samples of peripheral blood from AITP patients and control donors by density gradient centrifugation (Lymphoprep; Nycomed, Denmark). Cell viability determined by trypan blue exclusion was greater than 90% in all samples.
only. 
Statistical Analysis
Non-parametric Chi-square and Fisher Exact Tests were used for statistical analysis, with p < 0.05 considered to represent significance.
Results
Mapping peptides derived from the GPIIIa sequence that stimulate proliferation by
PBMC from AITP patients or healthy controls
The prime aim was to identify the peptide sequences from GPIIIa that contain Th epitopes.
PBMC were obtained from the group of 31 patients with AITP (clinical details summarized in 17, 18 , as would be expected for autoaggressive lymphocytes of pathogenic relevance. Therefore, to map the epitopes recognized by these cells, the culture conditions were based on those previously designed to favor fast developing recall, rather than slower primary, responses [28] [29] [30] 36 .
Representative results from four AITP patients, demonstrating GPIIIa peptides that elicit PBMC proliferation, are illustrated in Figure 1 , and the stimulatory peptides for each of the 31 patients are listed in Table 3 . It can be seen that PBMC from all but three patients responded to at least one member of the peptide panel, and that, typically, multiple sequences induced proliferation.
The presence of anti-platelet antibodies reactive with GPIIb/IIIa was confirmed in 27 of the 31 AITP patients ( to peptides. However, in these cases it was possible to screen only sera for anti-GPIIb/IIIa, and the testing of platelet eluates was often necessary to detect the antibody. Figure 2 , with the data summarized in Table 4A Table   4B , with representative examples illustrated in Figure 3 ). It can be seen that, as in the healthy donors, responses to GPIIIa peptides in this disease control group are very infrequent.
Distribution of stimulatory peptides on the platelet GPIIIa
Despite variation between AITP patients in the profile of GPIIIa peptides that elicited PBMC proliferation (Table 3) , particular peptides were identified as dominant, since they stimulated 
Variation over time in the pattern of GPIIIa peptides that stimulate responses
Longitudinal studies of patients with chronic autoimmune diseases other than AITP 28, 40, 41 demonstrate changes over time in the identities of autoantigen-derived peptides recognized by autoaggressive Th cells. To establish whether the same is true for AITP, serial PBMC samples taken over periods of weeks or months from patients (n=10) were screened for responsiveness to the GPIIIa peptide panel. only.
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Role of HLA Class II in responses of PBMC from AITP patients and control donors
In order to demonstrate functionally that the lymphocytes responding to GPIIIa peptides came from the Th subset, which is restricted by MHC Class II molecules, blocking antibodies specific for anti-HLA-DP, -DQ and -DR were tested for the ability to inhibit the responses. HLA type is one of the factors that can influence predisposition to particular immunemediated diseases. The panels of AITP patients and healthy controls were typed for HLA-DR and HLA-DQ polymorphic beta chain genes (Tables 3 and 4A) , and the results compared with published data from the general UK population 42 . The commonest alleles at each locus amongst patients were, respectively, DRB1*03 and DRB1*15, and DQB1*03 and DQB1*06, but there were no significant positive or negative associations with the disease or the ability of particular sequences to stimulate proliferation. 
Discussion
This report identifies the peptide epitopes from the platelet autoantigen GPIIIa that are recognized by Th cells from patients with AITP, and describes seven dominant sequences.
Autoreactive Th cells specific for platelet glycoprotein are known to be activated in AITP For For . Th cells from patients with AITP do not respond in vitro to purified GPIIIa, but only to enzyme treated or recombinant fragments 17, 18 , indicating that the relevant epitopes are to some degree cryptic in vitro, and not necessarily available from the antigen in its native conformation. Hence, it is plausible that at least some of the dominant peptides identified here may, in turn, be processed inefficiently in vitro from the recombinant fragments, which would therefore stimulate fewer responses that expected in comparison with the peptide panel. The stimulatory peptides may nonetheless be relevant to disease, in the different processing environment in vivo 44 .
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The need for specific, effective and safe treatment for patients with chronic AITP may be met by the development of peptide immunotherapy to re-induce Th tolerance to the platelet glycoproteins. It has been shown from animal models of other autoimmune diseases 11, 12, 24 that peptides containing dominant Th cell epitopes can prevent responses to the corresponding antigen when given in soluble form without adjuvant, or if administered by a tolerogenic mucosal route. Importantly, induction to tolerance to only one dominant epitope, particularly if mediated by active immune regulation, can ablate responsiveness to the entire autoantigen from which it is derived, and also to other, associated antigens by a process of bystander only.
For Similar results were obtained with PBMC from another three patients.
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